Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05920434
Other study ID # Manuscript: NS-D-22-012
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 19, 2020
Est. completion date March 22, 2021

Study information

Verified date June 2023
Source Adiyaman Provincial Health Directorate
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Introduction: Pain relief in diabetic neuropathy is one of the main goals of treatment. Foot reflexology and foot bath, which are two of the important applications of holistic approaches, reduce pain and can significantly increase the quality of life. Objective: In the current study, it was aimed to examine the effects of foot reflexology and foot bath applied to diabetic individuals with neuropathic pain on pain and quality of life. Method: In this randomized controlled study, the sample was randomized into three groups: (I) Foot reflexology (n: 30), (II) Foot bath (n: 30), and (III) Control (n: 30). The "Patient Information Form", "DN4 Pain Questionnaire", "Neuropathic Pain Impact on Quality-of-Life questionnaire (NePIQoL)", and "Visual Analog Scale (VAS)" were used to collect research data. In the study, a protective sensory examination was also performed with the Semmes-Weinstein Monofilament (SWM) Test and the Vibration Test (128 Hz diapason). Apart from these, foot care training was given to all patients included in the practice groups as the role of the diabetes nurse, based on the diabetic foot care training prepared by the Turkish Diabetes Association.


Description:

(I) Foot reflexology group Individuals in the foot reflexology group were treated by the researcher once a week for a total of 60 minutes, 30 minutes on each foot, for 6 weeks. (II) Foot bath group In the first meeting, each patient in the foot bath group was informed about the way of doing a footbath in practice. Each patient in the foot bath group was asked to apply a foot bath for 10 minutes, 3 times a week, and twice a day for 6 weeks. A plastic foot bath tub (42 x 37 x 12 cm) without a massage function is provided for each of the patients (Figure 2D). In order not to miss the applications, the patient was followed up by phone on the specified days (3 times a week, Monday-Wednesday-Friday). The patient was told that the foot bath water should be at 40 degrees celsius and that his feet should be kept in water for 10 minutes, approximately 10 cm above the ankle 25. The patient came to the clinic for the forms and protective sensory examination in the 2nd, 4th, and last week. Control group Forms and protective sensory examination tests were applied to the patients in the control group, as in the intervention groups, and no application was made other than standard nursing care.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date March 22, 2021
Est. primary completion date August 21, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants diagnosed with diabetes and the value of HgbA1c = 6.5, - Participants with the DN4 = 4, - Participants with the VAS = 4. Exclusion Criteria: - Participants who were pregnant - Participants who received any other complementary therapy during the period of the study, - Participants who had history of systolic blood pressure lower than 100 mmHg in the past, - Participants who were taking systemic corticosteroids in the previous month, - Participants who with peripheral artery disease, gonarthrosis, spinal disc herniation, ankle tendonitis, active foot ulcer, and infection - Participants who had histories of Kidney, heart and brain diseases, rheumatic diseases, thyroid diseases, other hormonal disorders, and malignancy,

Study Design


Related Conditions & MeSH terms


Intervention

Other:
randomized controlled study
randomized controlled study,no drugs or devices were administered to the participants.

Locations

Country Name City State
Turkey Reva Gundogan Adiyaman

Sponsors (1)

Lead Sponsor Collaborator
Adiyaman Provincial Health Directorate

Country where clinical trial is conducted

Turkey, 

References & Publications (1)

Zakin E, Abrams R, Simpson DM. Diabetic Neuropathy. Semin Neurol. 2019 Oct;39(5):560-569. doi: 10.1055/s-0039-1688978. Epub 2019 Oct 22. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other The quality of life Neuropathic Pain Impact on Quality-of-Life Questionnaire (NePIQoL)-The scale consists of 42 items in total and the item answer options are in the form of a 5-point Likert scale.Except for items 12, 15, 33, 34, which are reverse scored, all items are scored from 5-1; 5 is 'strongly agree' or 'always' and 1 is 'strongly disagree' or 'no, never'. The total score range varies between 42 and 210 .A high score on the scale indicates a low quality of life. 6 weeks
Primary Pain scores Douleur Neuropathique 4 Questions -It consists of 10 questions in total. The total scale score is calculated by giving 1 point for the yes answer given by the patient to each of the questions and examination findings, and 0 points for the no answer. The lowest score is 0, the highest 10 points can be obtained. is evaluated. 6 weeks
Primary Pain severity Visual Analog Scale (VAS)-It is an equidistant scale on a 10 cm horizontal plane, on one side of which there is no pain and on the other side the pain is "unbearable". The patient is asked to mark the point on this line that best expresses the severity of his or her pain. This distance, measured in millimeters, is interpreted as a "score" .For pain severity, 0 points are "no pain" and 10 points are "worst unbearable pain". evaluated as. 6 weeks
Secondary Sensory level Semmes-Weinstein Monofilament (SWM) Test-During the test, the monofilament designed to apply 10 grams of pressure to the patients is touched to the designated areas of the foot until it forms the letter C. Pressure is applied to three different areas (1st metatarsal head, plantar surface of distal hallux, 5th metatarsal plantar surface) on both feet for one second, sufficient to bend the monofilament, and patients are asked whether they feel this pressure. Expression of pressure by the patient in at least two of the three areas on the plantar surface of the foot indicates sensory loss. 6 weeks
Secondary Vibration sense Vibration Test (128 Hz) diapason-It is applied to the patients in the supine position with 128 Hz Diaposan.The tuning fork is placed perpendicularly and steadily on the dorsal surface of the distal phalanx of the first toe of the foot .The felt vibration time is recorded and if the patient feels the tuning fork vibration after 10 seconds, it is considered as no vibration sense. 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT04988321 - Theta Burst Brain Stimulation in Diabetic Neuropathy Patients With Neuropathic Pain: Investigating Neural Mechanisms N/A
Completed NCT00385671 - An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain Phase 4
Completed NCT00159679 - Pregabalin in the Treatment of Pain Due to Diabetic Peripheral Neuropathy Phase 4
Completed NCT00141401 - Safety and Efficacy of Pregabalin in Patients With Diabetic Peripheral Neuropathy. Phase 3
Active, not recruiting NCT04469270 - Study to Assess Safety and Efficacy of Engensis in Painful Diabetic Peripheral Neuropathy Phase 3
Completed NCT00553475 - Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Pain Associated With Diabetic Peripheral Neuropathy Phase 3
Completed NCT00381719 - Safety and Efficacy of AGN 203818 in Patients With Painful Diabetic Peripheral Neuropathy Phase 2
Completed NCT00539175 - Treatment of Painful Diabetic Neuropathy With Photon Stimulation N/A
Completed NCT00058968 - A Study for the Treatment of Painful Diabetic Neuropathy Phase 3
Completed NCT05029297 - Study With Two Capsaicin Topic Treatments in Diabetic Neuropathy. Phase 3
Completed NCT02215252 - A Clinical Trial To Evaluate PF-05089771 On Its Own And As An Add-On Therapy To Pregabalin (Lyrica) For The Treatment Of Pain Due To Diabetic Peripheral Neuropathy (DPN) Phase 2
Completed NCT00785577 - A Study for Treatment of Pain in Patients With Diabetic Neuropathy. Phase 2
Completed NCT00858351 - Thermal Biofeedback for the Treatment of Diabetic Neuropathy N/A
Completed NCT03047278 - Transporters for Organic Cations and Glycemic Control in Patients With Neuropathic Pain. Phase 4
Completed NCT01628627 - Frequency Modulated Neural Stimulation (FREMS) in Symptomatic Diabetic Neuropathy Phase 4
Completed NCT03315598 - Evaluation of an Effectiveness and Safety of the Electroacupuncture in the Management of Intractable Neuropathic Pain N/A
Completed NCT01057693 - Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy Phase 3
Completed NCT01564459 - Study to Evaluate MK-6096 in the Treatment of Painful Diabetic Neuropathy (PDN) in Adults (MK-6096-021) Phase 2
Recruiting NCT01214590 - Preliminary Assessment of the Efficacy of the VascuActive™ Device on Diabetic Peripheral Neuropathy N/A
Completed NCT01089556 - A Study in Painful Diabetic Neuropathy Phase 3

External Links